Treating patients for cardiovascular protection: combination therapy to achieve complete renin-angiotensin system...

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Pharmacology

Background:

• Renin-angiotensin system (RAS) inhibition via ACE inhibitors or ARBs is a validated antihypertensive strategy.
• Chronic RAS activation has detrimental pathophysiologic effects, suggesting RAS inhibition offers benefits beyond blood pressure control.
• Monotherapy with ACE inhibitors or ARBs demonstrates efficacy in slowing renal disease progression and providing vascular protection in high-risk individuals.

Purpose of the Study:

• To review the rationale for dual RAS inhibition.
• To present clinical data on the efficacy of combined ACE inhibitors and ARBs.
• To discuss ongoing studies evaluating dual RAS inhibition in high-risk cardiovascular patients.

Main Methods:

• Literature review of studies on RAS inhibition.
• Analysis of clinical trial data for ACE inhibitors and ARBs.
• Examination of evidence for dual RAS blockade efficacy and safety.

Main Results:

• ACE inhibitors and ARBs individually slow renal disease progression.
• RAS inhibition provides vascular protection, even without significant blood pressure changes.
• Dual RAS blockade aims for more complete inhibition and potentially greater cardiovascular risk reduction.

Conclusions:

• Dual RAS inhibition is a promising strategy for enhanced cardiovascular risk reduction.
• Further research is ongoing to fully evaluate the utility of combined ACE inhibitors and ARBs.
• This approach may offer significant benefits for patients at high risk for cardiovascular events.